Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.

Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, Lee L, Bhojwani D, Horton TM, Belitskaya-Levy I, Greenberger LM, Horak ID, Grupp SA, Teachey DT, Raetz EA, Carroll WL.

Leukemia. 2012 Feb;26(2):271-9. doi: 10.1038/leu.2011.199. Epub 2011 Aug 16.

2.

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.

Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM.

Blood. 2011 Aug 25;118(8):2191-9. doi: 10.1182/blood-2011-04-351239. Epub 2011 Jun 28.

3.

Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice.

Shen X, Zheng JY, Shi H, Zhang Z, Wang WZ.

Am J Med Sci. 2012 Jul;344(1):52-8. doi: 10.1097/MAJ.0b013e318239c4ee.

PMID:
22261621
4.

Targeting survivin and p53 in pediatric acute lymphoblastic leukemia.

Tyner JW, Jemal AM, Thayer M, Druker BJ, Chang BH.

Leukemia. 2012 Apr;26(4):623-32. doi: 10.1038/leu.2011.249. Epub 2011 Sep 30.

5.

Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition.

Liu X, Gao R, Dong Y, Gao L, Zhao Y, Zhao L, Zhao X, Zhang H.

BMC Cancer. 2010 Aug 10;10:418. doi: 10.1186/1471-2407-10-418.

6.

Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.

Carew JS, Espitia CM, Zhao W, Mita MM, Mita AC, Nawrocki ST.

Mol Cancer Ther. 2015 Jun;14(6):1404-13. doi: 10.1158/1535-7163.MCT-14-1036. Epub 2015 Mar 25.

7.

Reversal of drug resistance by silencing Survivin gene expression in acute myeloid leukemia cells.

Wu YH, You Y, Chen ZC, Zou P.

Acta Biochim Pol. 2008;55(4):673-80. Epub 2008 Dec 18.

8.

Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies.

Shinozawa I, Inokuchi K, Wakabayashi I, Dan K.

Leuk Res. 2000 Nov;24(11):965-70.

PMID:
11086180
9.

Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.

Chen L, Liang L, Yan X, Liu N, Gong L, Pan S, Lin F, Zhang Q, Zhao H, Zheng F.

Int J Gynecol Cancer. 2013 Feb;23(2):256-63. doi: 10.1097/IGC.0b013e31827ad2b8.

PMID:
23358177
10.

Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia.

Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH, Jung HL, Koo HH, Kim HJ, Kang HJ, Shin HY, Ahn HS.

Blood. 2007 Jan 15;109(2):471-7. Epub 2006 Sep 21.

11.

Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy.

Kunze D, Erdmann K, Froehner M, Wirth MP, Fuessel S.

Int J Mol Sci. 2013 Jun 7;14(6):12297-312. doi: 10.3390/ijms140612297.

12.

[Gene expression of livin and survivin in adult patients with acute lymphoblastic leukemia and its clinical significance].

Li WQ, Li XL, Wang GP, Fu B.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):921-5. Chinese.

PMID:
21867615
13.

Silencing survivin expression inhibits the tumor growth of non-small-cell lung cancer cells in vitro and in vivo.

Zhang K, Li Y, Liu W, Gao X, Zhang K.

Mol Med Rep. 2015 Jan;11(1):639-44. doi: 10.3892/mmr.2014.2729. Epub 2014 Oct 21.

PMID:
25333812
14.

Validation by RQ-PCR and flow cytometry of alpha-defensin1-3 (DEFA1-3) overexpression in relapsed and refractory acute lymphoblastic leukemia.

Te Kronnie G, Bicciato S, Franceschini L, Accordi B, Dellíorto MC, Rinaldi A, Pession A, Barisone E, Conter V, Locatelli F, Basso G.

Oncol Rep. 2006 Feb;15(2):341-6.

PMID:
16391852
15.

Overexpression of BMI-1 correlates with drug resistance in B-cell lymphoma cells through the stabilization of survivin expression.

Bhattacharyya J, Mihara K, Ohtsubo M, Yasunaga S, Takei Y, Yanagihara K, Sakai A, Hoshi M, Takihara Y, Kimura A.

Cancer Sci. 2012 Jan;103(1):34-41. doi: 10.1111/j.1349-7006.2011.02121.x. Epub 2011 Nov 20.

16.

Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin.

Tian H, Liu S, Zhang J, Zhang S, Cheng L, Li C, Zhang X, Dail L, Fan P, Dai L, Yan N, Wang R, Wei Y, Deng H.

J Biomed Nanotechnol. 2012 Aug;8(4):633-41.

PMID:
22852473
17.

miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.

Hu Y, Xu K, Yagüe E.

Breast Cancer Res Treat. 2015 Jun;151(2):269-80. doi: 10.1007/s10549-015-3372-9. Epub 2015 Apr 22.

PMID:
25900794
18.

YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.

Kumar B, Yadav A, Lang JC, Cipolla MJ, Schmitt AC, Arradaza N, Teknos TN, Kumar P.

Mol Cancer Ther. 2012 Sep;11(9):1988-98. doi: 10.1158/1535-7163.MCT-12-0167. Epub 2012 Jun 21.

19.

Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.

Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW, Kavallaris M.

J Natl Cancer Inst. 2006 Oct 4;98(19):1363-74.

PMID:
17018783
20.

Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.

Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, Kaneko N, Sasamata M.

Clin Cancer Res. 2011 Aug 15;17(16):5423-31. doi: 10.1158/1078-0432.CCR-10-3410. Epub 2011 Jul 7.

Supplemental Content

Support Center